FAQs

The GFPD Patient Registry for Peroxisomal Disorders

Thank you for your interest in The GFPD Patient Registry for Peroxisomal Disorders. Please see below some frequently asked questions. If you have additional questions that are not listed, please contact us!

1. What is the purpose of The GFPD Patient Registry for Peroxisomal Disorders?

The purpose of The GFPD Patient Registry for Peroxisomal Disorders is to bring the peroxisomal disorders community together and collect data. Some of the goals of The GFPD Patient Registry for Peroxisomal Disorders are:

To describe the people who have peroxisomal disorders and to better understand the stages of the disease and the different ways peroxisomal disorders impact individuals through their lifespan. To do this, we will ask about diagnosis, treatment, medical history, social and economic environment, and treatment outcomes.
To better understand the progression of peroxisomal disorders over a person’s lifetime and to learn about clinical practice patterns and variations over the course of treatment.
To help to develop best practices, management guidelines, and recommendations so that clinicians can know how to give the best care to improve the quality of life and outcomes of individuals with peroxisomal disorders.
To identify individuals with peroxisomal disorders who might be willing to take part in other research studies or clinical trials. You will be able to choose whether you want to hear about these other studies.

2. What is a Patient Registry?

A patient registry is a collection of standardized information about a group of patients who share a condition. The information may be used for a variety of purposes such as conducting natural history studies and supporting disease specific clinical trial recruitment.

3. What is a Natural History Study?

A natural history study is a study designed to track the course of a disease over time. It includes people who have a specific medical condition or disease. It may also include those who are at risk of developing the condition/disease. This type of research identifies demographic, genetic, environmental, and other information that may be common within the disease and its outcomes. A natural history study can also show the differences in symptoms and changes over time that are seen in different people with the same disease. Natural history studies often aim to find unknown similarities within the disease population. They have many potential uses such as patient care best practice development and clinical trial recruitment. Data for natural history studies are often collected via patient registries.

4. How is the data collected?

Data is collected through a secure web-based application developed by the National Organization for Rare Disorders, Inc. (NORD®) This application will host our patient registry and can be accessed by computer, tablet or phone.

The patient registry is maintained on the IAMRARE platform by NORD, who also provides ongoing technical support of the system. The GFPD provides the day-to-day management of The GFPD Patient Registry for Peroxisomal Disorders.
Study participants respond to questions grouped within a series of surveys developed per study standards and in collaboration with disease specific experts.
Eventually, the Advisory board may determine that it would be valuable to include the registry data on a data sharing platform. An example would be the FDA-sponsored Rare Disease Cure Accelerator – Data and Analytics Platform (RDCA-DAP). Such data will be shared without identifiers

5. What types of data will be collected in The GFPD Patient Registry for Peroxisomal Disorders?

The data collected includes but is not limited to:

Socio-demographics
Medical and diagnostics
Treatment and disease progression
Management of care
Quality of life

6. What is a Research Study Sponsor?

A Research Study Sponsor is an individual, company, institution, or organization. They are responsible for choosing appropriately trained and experienced researchers to conduct the study. They are also responsible for the initiation and management of a research study. Additionally, the sponsor is responsible for the costs associated with conducting a registry study. They ensure that the study is conducted in a reputable, ethical manner, and upholds regulations as they apply to the study. The sponsor of this registry is the Global Foundation for Peroxisomal Disorders.

7. Who is the Global Foundation for Peroxisomal Disorders (GFPD)?

The mission of the GFPD is to improve the lives of individuals with peroxisomal disorders by funding research, championing scientific collaboration, and empowering families and professionals through educational programs and support services. Through connections with medical and scientific professionals and family support networks, our foundation is a resource for families who have received a diagnosis of a peroxisomal disorder in the Zellweger spectrum or the related single enzyme protein deficiencies.

8. What is a Principal Investigator?

The Principal Investigator is the person with the primary responsibility for the design and conduct of the research project or study. The PI is responsible for oversight of all aspects pertaining to the conduct of the Registry, its staff and the research on the data contained within. Abby Pelster, MS, CCC-SLP is the Principal Investigator for The GFPD Patient Registry for Peroxisomal Disorders. Abby Pelster is a speech-language pathologist with 14 years of experience. Prior to working at the University of Nebraska-Lincoln as a lecturer and clinical supervisor, Abby worked with all ages of children in both the public schools and pediatric clinics. She was introduced to the GFPD after meeting an individual with a peroxisomal disorder and has continued her involvement with the organization since its first conference in 2011.

9. Who is a Study Participant?

A Study Participant is the individual about whom information is entered into the registry. In the case of an independent person of legal age, this individual will consent for and enter information about themself. If an individual is not of legal age or is an adult who requires someone to act on their behalf, a person (LAR, see below) who is legally responsible for their health care will provide consent and enter information about the Study Participant. If the Study Participant is deceased, a designated representative will provide consent and enter information about the Study Participant on their behalf.

10. What is a Legally Authorized Representative (LAR)?

An LAR is someone who is authorized under applicable law to consent and enter data in the registry on behalf of another individual. The LAR may be a parent, grandparent, spouse, caregiver, or guardian as long as they have the legal authority to grant consent on behalf of that individual. An LAR will sign up on the IAMRARE platform with a Caregiver account. When an LAR acts on behalf of a study participant, they are considered to be the reporter in the research.

11. What is a Designated Representative?

A Designated Representative is someone who is authorized to consent and enter data in the registry on behalf of a deceased individual with a peroxisomal disorder. The Designated Representative may be a parent, grandparent, spouse, caregiver, or guardian as long as they have the legal authority to grant consent on behalf of the deceased individual. This person must have had knowledge of and participated in the medical care of the deceased. These individuals are permitted to enter retrospective data on their behalf.

12. What is an Informed Consent Form (ICF)?

An ICF is a document that provides potential participants with key information about the registry. This document helps potential participants to make an informed decision whether to join or not. Information will include topics such as: the risks and benefits of the research project, use of data, and participant privacy. If they choose to join the study, participants are required to electronically sign the ICF. This indicates that they agree to the terms as described before entering data into the registry or responding to surveys.

13. After consenting, can a Participant choose to stop participating in the study?

Participants are able to withdraw from the study at any time. However, researchers may still use the information that they have collected prior to the participant changing their mind. Information that has already been shared with researchers prior to withdrawal cannot be retrieved or removed.

14. What is an Institutional Review Board (IRB)?

An IRB is a board formally designated by an institution or investigator to review, approve the initiation of, and conduct periodic review of research involving people. The primary purpose of such an assessment is to assure the protection of the rights and welfare of the participants in the study. This is also known as an Ethics Committee (EC) or Research Ethics Board (REB in Canada).

15. Who can join the study?

This study is open to anyone who has a peroxisomal disorder diagnosis and meets the study inclusion criteria for participation.

16. Is there a cost to participate?

There is no cost to the patient to join this study.

17. Is there a payment for participating?

You will not be paid for the information you provide. Periodically, GFPD may implement a thank you program for Participants for providing their information to The GFPD Patient Registry for Peroxisomal Disorders.

18. How long will this study last?

A registry on the IAMRARE platform will typically be open for at least five years. Participants will be asked to return to the registry periodically to update their information.

19. Can data be collected worldwide?

The registry uses an online platform which allows participants to contribute data from anywhere in the world. Individuals from other countries who enter data into the registry should be aware that data and privacy laws are different in the U.S. from other countries. This U.S. based registry will protect data and privacy according to U.S. requirements.

20. What are the GDPR considerations?

For individuals living outside the United States who choose to share information about themselves, the same protections for privacy and confidentiality are offered as in the United States. Residents of the European Union and Switzerland have additional particular rights related to personal information. This information is disclosed within the informed consent document. If an individual signs this document, they acknowledge that they are disclosing information that would otherwise be private. Privacy laws in an individual’s country may have different protections than those provided in the United States.

Registry participants who are residents of the European Union and Switzerland are entitled to:

Request to obtain access to and rectification or erasure of personal data;
Receive personal data in a portable, readily-accessible format;
Restrict or withdraw permission for the processing of personal information; and
Lodge a complaint with an appropriate supervisory authority.

21. Where is the data stored?

NORD stores Sponsor and Participant Registry Data on NORD encrypted servers and/or encrypted servers of third-party vendors hosted in Canada. Regular back-up at commercially acceptable intervals is provided. These servers meet industry standards and are compliant with US and international regulations, including GDPR.

22. Is the data safe?

The registry follows strict government guidelines to assure patient information is protected. The platform is served over HTTPS, which means that the data is encrypted when being sent from the user’s browser to the NORD servers. The data is also kept encrypted in the NORD database. Communications between the registry platform application server and the database are also encrypted. As with any information you provide electronically, there is a very rare chance that your privacy could be compromised. However, the registry and the security measures minimize the chance of this occurring.

23. Who owns the data?

The study data are owned by the study sponsor, the GFPD. The GFPD decides how and with whom to share the data. NORD staff will have access to the data for activities related to support and maintenance of the Platform and will collect Platform-wide participation statistics. The specifics will be outlined in your informed consent.

24. Who will have access to Protected Health Information (PHI)?

All data, including those with PHI, will be stored in a password protected secure server. Access to PHI will be limited to:

Approved members of The GFPD Patient Registry for Peroxisomal Disorders research team
NORD staff, in cases where technical support is needed and with the permission of registry staff
With agreement from the Sponsor, NORD may conduct IRB-approved, cross-disease research using registry data.

In all cases, your privacy will be protected. The Registry Advisory Board will evaluate all requests for data from researchers. Researchers will only be provided with the minimum data necessary to accomplish their research study goals. Data containing PHI will only be shared if the research cannot be done without it. The researchers will be required to sign a Confidentiality Agreement in which they promise to keep your information safe.

25. How is the registry maintained?

The registry is maintained by NORD who hosts the registry on its web-based application. NORD provides ongoing technical support of the system. The GFPD provides the day-to-day management of their patient registry.

26. What if I need help completing the registry?

GFPD Registry Staff can help you complete the registry by phone or Zoom as necessary. Please contact registry staff at 843-796-8080 or patientregistry@thegfpd.org and someone will be in contact with you with details.

27. What is a Registry Advisory Board?

A Registry Advisory Board is a committee that may include scientists, doctors, parents, and patient advocates. They oversee the conduct of the study. The board advises on the development of surveys and reviews combined registry data and the use of this registry. They will ensure proper evaluation of all research requests for use of the registry data. They will also review any protocol or confidentiality deviations and ensure that any such deviations are reported to the IRB.

28. Who is NORD – the National Organization for Rare Disorders, Inc.?

NORD, an independent nonprofit, is leading the fight to improve the lives of rare disease patients and families. We do this by supporting the rare community, its people, and organizations. We work together to accelerate research, raise awareness, provide valuable information, and drive public policy that benefits the estimated 25-30 million Americans impacted by rare diseases.

Learn more about NORD at https://rarediseases.org/.